Drug Discovery Services Market

Drug Discovery Services Market Size by Process (Target Selection, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small Molecule, Biologics), Therapeutic Area (Oncology, Neurology, Infectious), End User (Pharma, Biotech, Academic) & Region - Global Forecast to 2028

Report Code: PH 5682 Mar, 2023, by marketsandmarkets.com

The size of global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028. The research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Increasing research and development investments made by pharmaceutical and biopharmaceutical companies, growing R&D pipeline for pharmaceutical drugs influencing the growth in demand for outsourcing the analytical testing services, global initiatives made for research on rare disease and orphan drugs, and maximized cost of in-house development of drugs are driving the growth for market. Also, technological advancements, the introduction of new drug discovery techniques, the expiry of patents, and rising demand for specialized testing services among end users are expected to offer growth opportunities to players in this market. However stringent regulation concerning animal use for drug discovery and the shortage of skilled professionals prove to be an restraint and challenge for drug discovery service providers.

Attractive Opportunities in the Drug Discovery Services Market

Drug Discovery Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

Drug Discovery Services Market Dynamics

DRIVER: Growing R&D Expenditure in Pharma-Biotech Sector

Drug discovery and development have seen significant growth over the last decade in terms of clinical studies and the introduction of novel drug molecules. As per ClinicalTrials.gov, the number of registered studies went up from 32,517 in 2019 to 36,770 in 2022, at a CAGR of 4.2%. Companies operating in the Pharmaceutical and biopharmaceutical industry invest laboriously in developing novel drugs. Biopharmaceutical companies spend resources for research and development to deliver high-quality and innovative products to gain market capital. After studying the recent industry trends, it was observed that the leading pharma companies are increasing their R&D capabilities through significant R&D investments to see capital returns in long term and through collaborative R&D efforts. In a recent study published by Evaluate Pharma, the worldwide pharmaceutical R&D spending was valued at USD 144 billion in 2014, and this figure is estimated to reach USD 285 billion by 2028.

The growing R&D spending by pharmaceutical and biopharmaceutical companies is encouraging them to go for fully integrated or functional outsourcing services for drug discovery and development, from the early development stage to the late-stage development phase. The pharmaceutical companies have budget constraints and need to contain fixed costs, hence outsourcing has evolved as a strategic alternative to overcome the lack of in-house resources required for new product development. Major pharma companies are transitioning to a leaner business model that is dependent heavily on outsourcing. Many pharmaceutical and biopharmaceutical companies prefer to outsource their testing functions during R&D to improve profitability, meet the timelines involved in drug development, and save costs. This can be confirmed from the recent agreements by major pharmaceutical companies with CROs providing drug discovery and development services. Thus, increasing pharmaceutical R&D expenditure supports the growth of the market.

RESTRAINT: Stringent regulations governing drug discovery and animal usage

The major focus of regulatory authorities during drug approval is securing safety and efficacy. Even if these approaches confirm the quality of the products launched in the market, they significantly increase the cost of drug development process of the final product. For regions with price-sensitive emerging markets, this factor can significantly impact the uptake of a particular drug. Aside from this, multiple legislations that ensure the quality of the product (such as GMP and GLP) usually increases the manufacturing costs.

Also, there are strict guidelines govern the usage of animals in drug discovery. Mice, rats, fish, amphibians, and reptiles are the most used animals in any research. Scrutiny regarding the ethical use of animals in research has pushed governments to introduce legislation for animal safety and use, which presents several challenges to the smooth functioning of drug discovery research, and this has reinforced companies to implement other techniques to minimize animal use. For example, Novo Nordisk uses biosimulation, which uses computer models to simulate human biology. However, this has not been fully adopted across the industry.

Computer modeling is another new technology used to predict drug metabolism. However, this computer modeling technique, in silico, is still gaining support and remains in the early phase of industry adoption. It is being tested and is not expected to surpass animal testing during the forecast period fully. The viability of these AI models compared to animal models is being studied; hence, while animal usage concerns may be bypassed in the future, they are expected to restrain the market over the forecast period.

OPPORTUNITY: Technological advancements and new drug discovery techniques

Technological innovations play a significant role in increasing the efficiency and time-to-market for new drugs that are being discovered. Larger CROs have been at the forefront of this innovation. Some prominent solutions have been listed below:

  • Next-generation proteomics: Proteomics technologies such as mass spectrometry are being considered powerful tools to deliver significant insights across every stage of the oncology drug discovery pipeline—for instance, helping uncover and validate novel drug targets, helping to understand drug mechanisms of action, and helping identify novel diagnostic, prognostic, or predictive biomarkers, etc.
  • 3D-bioprinting to create advanced drug models: 3D-bioprinting technology is considered a powerful tool for building tissue and organ structures for drug discovery. In general, bioprinting uses a 3D printer to accurately deposit cells and biomaterials into precise geometries to create anatomically correct biological structures. While traditional 3D printing uses metals, plastics, and polymers, bioprinting deals with living cells and biological matrices. Hence, there are significant challenges to transitioning from traditional 3D printing to bioprinting and ultimately achieving functional outcomes in bioprinted tissues.
  • Lab robotization and automation: Several companies are investigating lab automation and robotization with the help of AI for drug discovery. These include Strateos (US), Emerald Cloud Lab (US), and Arctoris Pte Ltd (Singapore), which are focused on AI-driven automated and robotized labs for drug discovery.
  • Quantum theory and quantum computing: The traditional computational method for modeling in synthetic and organic chemistry, medicinal chemistry, and drug design is molecular mechanics (MM). However, molecular mechanics has some limitations when studying electron-based properties within the drug-receptor microenvironment. Quantum mechanical (QM) methods substantially increase the accuracy of predictions and provide much more relevant models of chemical and biological objects and their interactions, but QM methods are costlier.
  • Cell-free DNA for drug discovery & Development: Cell-free DNA (cfDNA) will be central in identifying protein targets in the oncology area, assessing the efficacy of drugs targeting them in clinical trials, and identifying optimal combination therapies.

Such advancements in technology will significantly drive the market for drug discovery services.

CHALLENGE: Shortage of Skilled Personnel

The pharmaceutical and biopharmaceutical industry is constantly evolving at a fast pace and professionals need to keep pace with the dynamic changes in the pharmaceutical R&D technologies and methodologies, provide quality services, and comply with good laboratory practices. The drug discovery service providers face problems in gaining and retaining well trained and skilled professionals as they compete with pharmaceutical and biotechnology companies and academic and research institutions for qualified and experienced scientists.

To compete efficiently, companies have to offer higher compensations and other benefits; this may affect the finances and results of operations of players, especially small-scale analytical testing providers. Thus, shortage of skilled professionals may hamper the adoption of new technologies and methodologies and inhibit the growth of the market in the coming years.

Drug Discovery Services Market Ecosystem

The market ecosystem comprises raw material suppliers, drug discovery service providers, and end users such as pharmaceutical & biotech companies, academic institutes, small CROS, and clinical laboratories. Raw material suppliers and service providers offer various supplies and services, such as instruments, consumables, assays, kits, and accessories for drug discovery studies such as PK/PD, ADME, DMPK, and other studies. CROs partner with their clients to create a trial design, implementation, and management strategy. This long-term relationship enables the partners to conduct trials successfully and bring new products into the market. Over time, the volume of work contracted out can be expanded, depending on how comfortable both partners are about taking the partnership forward.

The prominent drug discovery service providers are Laboratory Corporation of America Holdings (US), Eurofins Scientific SE (Germany), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Wuxi AppTec (China), Syngene International Limited (India), Curia Global Inc. (US), Pharmaron Beijing Co., Ltd. (China), Piramal Enterprises Limited (India), Thermo Fisher Scientific Inc. (US), Jubilant Pharmova Limited (India), GenScript Biotech Corporation (US), Shanghai Medicilon Inc. (China), and Frontage Holdings Corporation (US).

Ecosystem Analysis: Drug Discovery Services Market

Drug Discovery Services Market Ecosystem

Source: Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

Based on type, Chemistry Services segment accounted for the largest market share of the drug discovery services industry

Based on type, the drug discovery services market is segmented into chemistry services and biology services. The chemistry services segment commanded the largest share of this market in 2022. Growth in this market segment is largely due to the widespread application of chemistry services in various early drug development phases to deliver robust drug candidates. The extensive chemistry usage in academics, biotechnology companies, and large pharmaceutical companies also supports market growth. Biology services are expected to grow at a slower rate over the forecast period.

Based on drug type, small molecule drugs segment accounted for the largest market share of the drug discovery services industry

Based on drug type, the drug discovery services market is segmented into small-molecule drugs and biologics based on drug type. Small-molecule drugs commanded the largest share of the market in 2022. The large share of this segment can be attributed to the ease of working with small molecules, their low cost, and the increasing number of start-ups and new entrants focusing on developing small-molecule drugs.

Based on therapeutic area, oncology segment accounted for the largest market share of the drug discovery services industry

Based on the therapeutic area, the drug discovery services market is broadly segmented into oncology, infectious diseases, neurological diseases, immunological diseases, endocrine and metabolic diseases, respiratory diseases, digestive system diseases, cardiovascular diseases, genitourinary diseases and women’s health, and other therapeutic areas. Oncology is the largest segment in this market owing to the high incidence of cancer, a growing number of research studies on cancer therapeutics, and the focus on bringing innovative cancer drugs into the market.

The North American market is projected to contribute the largest share for the drug discovery services industry.

The global drug discovery services market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for drug discovery services, with an estimated share in 2022, while Europe is the second-largest market. A well-established pharmaceutical industry, ongoing R&D studies, high R&D expenditure, growth in the biosimilars and generics markets, and the rising outsourcing of R&D services by pharmaceutical and biopharmaceutical companies in the region are driving the market growth. North America is the largest pharmaceutical market in the world, with many global pharmaceutical and biopharmaceutical giants headquartered in the region, such as Laboratory Corporation of America Holdings (US), Charles River Laboratories International, Inc. (US), Thermo Fisher Scientific (US), Frontage Holdings (US), Pfizer, Inc. (US), AbbVie, Inc. (US), Abbott Laboratories (US), and Johnson & Johnson (US). These companies outsource their drug discovery and drug development services to reduce the cost and time of drug development. This is indicative of the growth opportunities in the North American market.

Drug Discovery Services Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The drug discovery services market is dominated by a few globally established players such as Laboratory Corporation of America Holdings (US), Charles River Laboratories International Inc. (US), WuXi AppTec (China), and Thermo Fisher Scientific Inc (US), among others, are the key service providers that provided drug discovery services in last few years. Major focus was given to the deals, expansions, and new service launches due to the changing requirements of pharmaceutical and biopharmaceutical companies, academic and research institutes, and other end users across the world.

Scope of the Drug Discovery Services Industry

Report Metric

Details

Market Revenue Size in 2023

$20.6 billion

Projected Revenue Size by 2028

$41.3 billion

Industry Growth Rate

Poised to Grow at a CAGR of 14.9%

Market Driver

Growing R&D Expenditure in Pharma-Biotech Sector

Market Opportunity

Technological advancements and new drug discovery techniques

This report categorizes the drug discovery services market to forecast revenue and analyze trends in each of the following submarkets:

By Process
  • Target Selection
  • Target Validation
  • Hit-to-Lead identification
  • Lead Optimization
  • Candidate Validation
By Type
  • Chemistry Services
  • Biology Services
By Drug Type
  • Small-molecule drugs
  • Biologics
By Therapeutic Area
  • Oncology oncology, infectious diseases, neurological diseases, immunological diseases, endocrine and metabolic diseases, respiratory diseases, digestive system diseases, cardiovascular diseases, genitourinary diseases and women’s health
  • Infectious diseases
  • Neurological diseases
  • Immunological diseases
  • Endocrine and metabolic diseases
  • Respiratory diseases
  • Digestive System diseases
  • Cardiovascular diseases
  • Genitourinary diseases
  • Other Therapeutic Area (psychiatry, dermatology, ophthalmology, and orphan and rare diseases)
By End user
  • Pharmaceutical & Biotechnology companies
  • Academic Institutes
  • Other End Users (small CROs, IVD companies, and clinical laboratories)
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
    • Brazil
    • RoLATAM
  • Middle East and Africa (MEA)

Recent Developments of Drug Discovery Services Industry:

  • In February 2023, Charles River Laboratories (US) announced a multi-program agreement with Pioneering Medicines, an initiative of Flagship Pioneering (US), allowing access to its Logica AI platform to discover small-molecule drugs.
  • In February 2023, Evotec SE (Germany) and Related Sciences (US) expanded their partnership for an integrated multi-target drug discovery agreement. The two companies aimed to select, discover, and develop precisely targeted medicines for unmet patient needs.
  • In January 2023, Charles River Laboratories (US) acquired SAMDI Tech, Inc. (US), which offers label-free HTS solutions for drug discovery research. The acquisition offered CRL expertise in label-free HTS MS platforms and created a comprehensive library of drug discovery solutions.
  • In April 2022, Charles River Laboratories (US) and Valo Health, a data-driven AI company, launched Logica, an AI-powered drug discovery services

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 43)
    1.1 STUDY OBJECTIVES 
    1.2 DRUG DISCOVERY SERVICES INDUSTRY DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
    1.6 LIMITATIONS 
    1.7 STAKEHOLDERS 
    1.8 SUMMARY OF CHANGES 
           1.8.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 47)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
          FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2022
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 DRUG DISCOVERY SERVICES INDUSTRY GROWTH RATE PROJECTIONS 
          FIGURE 7 MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
          FIGURE 8 MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
           TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
           TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
           TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 59)
    FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 DRUG DISCOVERY SERVICES INDUSTRY, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET, 2022
 
4 PREMIUM INSIGHTS (Page No. - 63)
    4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 
          FIGURE 15 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MARKET, BY DRUG TYPE AND COUNTRY (2022) 
          FIGURE 16 SMALL-MOLECULE DRUGS HELD LARGEST SHARE OF NORTH AMERICAN DRUG DISCOVERY MARKET IN 2022
    4.3 MARKET SHARE, BY TYPE (2022) 
          FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.4 DRUG DISCOVERY SERVICES INDUSTRY: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023–2028
 
5 MARKET OVERVIEW (Page No. - 66)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 DRUG DISCOVERY SERVICES INDUSTRY: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Growing R&D expenditure in pharma-biotech sector
                                FIGURE 20 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028
                    5.2.1.2 Increasing drug R&D pipeline and rising reliance on outsourcing
                                FIGURE 21 ACTIVE PHARMACEUTICAL PIPELINE, 2012–2022
                    5.2.1.3 Initiatives for research on rare diseases and orphan drugs
                                FIGURE 22 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS (2013–2021)
                    5.2.1.4 High cost of in-house drug development
                                FIGURE 23 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulations governing drug discovery and animal usage
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Technological advancements and new drug discovery techniques
                    5.2.3.2 Rising demand for specialized testing services among end users
                    5.2.3.3 Patent expiries of key biologics
                                TABLE 5 US: BIOLOGICS GOING OFF-PATENT DURING 2023–2027
                    5.2.3.4 High growth prospects in emerging markets
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of skilled personnel
           5.2.5 DRUG DISCOVERY SERVICES MARKET TRENDS
                    5.2.5.1 Adoption of AI in drug discovery
                    5.2.5.2 Increased outsourcing to emerging Asian economies
                    5.2.5.3 CRO industry consolidation
                                TABLE 6 MARKET: PROMINENT ACQUISITIONS, 2023–2021
                    5.2.5.4 Integrated end-to-end R&D service offerings
    5.3 RANGES/SCENARIOS 
          FIGURE 24 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON MARKET GROWTH
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 
          FIGURE 25 REVENUE SHIFT AND NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 26 VALUE CHAIN ANALYSIS OF MARKET: HIT-TO-LEAD IDENTIFICATION AND LEAD OPTIMIZATION PHASES ADD MAXIMUM VALUE
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 27 ECOSYSTEM ANALYSIS: MARKET
          TABLE 7 SUPPLY CHAIN ECOSYSTEM
    5.7 TECHNOLOGY ANALYSIS 
    5.8 PRICING ANALYSIS 
           5.8.1 AVERAGE SELLING PRICE TREND ANALYSIS
                    TABLE 8 DRUG DISCOVERY AND DEVELOPMENT PROCESS & COST OVERVIEW (2018 VS 2022)
    5.9 REGULATORY ANALYSIS 
           5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 13 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.10.1 THREAT OF NEW ENTRANTS
           5.10.2 THREAT OF SUBSTITUTES
           5.10.3 BARGAINING POWER OF BUYERS
           5.10.4 BARGAINING POWER OF SUPPLIERS
           5.10.5 INTENSITY OF COMPETITIVE RIVALRY
    5.11 KEY CONFERENCES & EVENTS, 2022–2023 
           TABLE 14 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.12 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DRUG DISCOVERY SERVICES
           5.12.2 BUYING CRITERIA FOR DRUG DISCOVERY SERVICES
                     FIGURE 29 KEY BUYING CRITERIA FOR END USERS
 
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS (Page No. - 93)
    6.1 INTRODUCTION 
          TABLE 15 DRUG DISCOVERY SERVICES INDUSTRY, BY PROCESS, 2021–2028 (USD MILLION)
    6.2 TARGET SELECTION 
           6.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
                    TABLE 16 MARKET FOR TARGET SELECTION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 17 NORTH AMERICA: MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 EUROPE: MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 19 ASIA PACIFIC: MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 LATIN AMERICA: MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 TARGET VALIDATION 
           6.3.1 EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE TO PROMOTE MARKET GROWTH
                    TABLE 21 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 22 NORTH AMERICA: MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 23 EUROPE: MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 24 ASIA PACIFIC: MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 LATIN AMERICA: MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 HIT-TO-LEAD IDENTIFICATION 
           6.4.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE
                    TABLE 26 MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 27 NORTH AMERICA: MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 28 EUROPE: MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 29 ASIA PACIFIC: MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 LATIN AMERICA: MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 LEAD OPTIMIZATION 
           6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION
                    TABLE 31 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 32 NORTH AMERICA: MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 33 EUROPE: MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 34 ASIA PACIFIC: MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 LATIN AMERICA: MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION)
    6.6 CANDIDATE VALIDATION 
           6.6.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES
                    TABLE 36 MARKET FOR CANDIDATE VALIDATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 37 NORTH AMERICA: MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 EUROPE: MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 39 ASIA PACIFIC: MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 40 LATIN AMERICA: MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE (Page No. - 109)
    7.1 INTRODUCTION 
          TABLE 41 DRUG DISCOVERY SERVICES INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
    7.2 CHEMISTRY SERVICES 
           7.2.1 CHEMISTRY SERVICES TO DOMINATE SERVICE TYPE MARKET
                    TABLE 42 CHEMISTRY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 43 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 44 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 45 ASIA PACIFIC: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 BIOLOGY SERVICES 
           7.3.1 RESTRICTIONS ON ANIMAL USAGE TO SLOW MARKET GROWTH
                    TABLE 47 BIOLOGY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 48 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 49 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 ASIA PACIFIC: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE (Page No. - 116)
    8.1 INTRODUCTION 
          TABLE 52 DRUG DISCOVERY SERVICES INDUSTRY, BY DRUG TYPE, 2021–2028 (USD MILLION)
    8.2 SMALL-MOLECULE DRUGS 
           8.2.1 SMALL-MOLECULE DRUGS TO HOLD LARGEST MARKET SHARE
                    TABLE 53 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 54 NORTH AMERICA: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 EUROPE: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 56 ASIA PACIFIC: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 57 LATIN AMERICA: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 BIOLOGICS 
           8.3.1 MARKET GROWTH OF BIOLOGICS & CHALLENGES ASSOCIATED WITH DISCOVERY TO DRIVE ADOPTION OF OUTSOURCING SERVICES
                    TABLE 58 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 EUROPE: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 62 LATIN AMERICA: MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 124)
    9.1 INTRODUCTION 
           TABLE 63 DRUG DISCOVERY SERVICES INDUSTRY, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
    9.2 ONCOLOGY 
           9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
                    FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS, 2012–2022 (THOUSAND)
                    TABLE 64 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2022)
                    TABLE 65 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 66 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 INFECTIOUS DISEASES 
           9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
                    TABLE 70 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 71 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 72 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 CARDIOVASCULAR DISEASES 
           9.4.1 HIGH MORTALITY RATES PROMPTING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
                    TABLE 75 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2022)
                    TABLE 76 MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 77 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 79 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 LATIN AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 NEUROLOGICAL DISEASES 
           9.5.1 INCREASING INVESTMENTS IN R&D FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET
                    TABLE 81 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2022)
                    TABLE 82 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 83 NORTH AMERICA: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 84 EUROPE: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 85 ASIA PACIFIC: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 86 LATIN AMERICA: MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.6 IMMUNOLOGICAL DISORDERS 
           9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
                    TABLE 87 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
                    TABLE 88 MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 89 NORTH AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 EUROPE: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 91 ASIA PACIFIC: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 92 LATIN AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.7 ENDOCRINE & METABOLIC DISORDERS 
           9.7.1 INCREASING DIABETIC POPULATION TO BOOST MARKET
                    FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
                    TABLE 93 MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 94 NORTH AMERICA: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 95 EUROPE: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 96 ASIA PACIFIC: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 97 LATIN AMERICA: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.8 RESPIRATORY DISORDERS 
           9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
                    TABLE 98 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS (2022)
                    TABLE 99 MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 100 NORTH AMERICA: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 101 EUROPE: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 102 ASIA PACIFIC: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 103 LATIN AMERICA: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.9 DIGESTIVE SYSTEM DISEASES 
           9.9.1 RISING DISEASE INCIDENCE DUE TO LIFESTYLE AND DIETARY CHANGES TO PROPEL MARKET
                    TABLE 104 MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2021–2028 (USD MILLION )
                    TABLE 105 NORTH AMERICA: MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 106 EUROPE: MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 107 ASIA PACIFIC: MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 108 LATIN AMERICA: MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH 
           9.10.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO BOOST MARKET
                    TABLE 109 DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 110 NORTH AMERICA: MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 111 EUROPE: MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 112 ASIA PACIFIC: MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 113 LATIN AMERICA: MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
    9.11 OTHER THERAPEUTIC AREAS 
           TABLE 114 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
           TABLE 115 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
           TABLE 116 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
           TABLE 117 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
           TABLE 118 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 DRUG DISCOVERY SERVICES MARKET, BY END USER (Page No. - 155)
     10.1 INTRODUCTION 
             TABLE 119 DRUG DISCOVERY SERVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             FIGURE 32 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011–2021
             TABLE 120 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
             TABLE 121 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 122 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 123 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 124 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
             10.2.1 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE
                        TABLE 125 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             10.2.2 TIER 1 COMPANIES
                        10.2.2.1 High investing capacity to drive growth
                                      TABLE 126 TOP PHARMA COMPANIES, BY REVENUE (2022)
                                      TABLE 127 MARKET FOR TIER 1 COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 128 NORTH AMERICA: MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 129 EUROPE: MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 130 ASIA PACIFIC: MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 131 LATIN AMERICA: MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
             10.2.3 TIER 2 COMPANIES
                        10.2.3.1 Limited investment capacity to slow market growth
                                      TABLE 132 MARKET FOR TIER 2 COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 133 NORTH AMERICA: MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 134 EUROPE: MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 135 ASIA PACIFIC: MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 136 LATIN AMERICA: MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
             10.2.4 TIER 3 COMPANIES
                        10.2.4.1 Insufficient technical advantages to restrain growth
                                      TABLE 137 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 138 NORTH AMERICA: MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 139 EUROPE: MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 140 ASIA PACIFIC: MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                      TABLE 141 LATIN AMERICA: MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
     10.3 ACADEMIC INSTITUTES 
             10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
                        TABLE 142 MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 143 NORTH AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 144 EUROPE: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 145 ASIA PACIFIC: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 146 LATIN AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
     10.4 OTHER END USERS 
             TABLE 147 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
             TABLE 148 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 149 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 150 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 151 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
 
11 DRUG DISCOVERY SERVICES MARKET, BY REGION (Page No. - 172)
     11.1 INTRODUCTION 
             TABLE 152 DRUG DISCOVERY SERVICES INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022)
             TABLE 153 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 154 NORTH AMERICA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 155 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 156 NORTH AMERICA: SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
             TABLE 157 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
             TABLE 158 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             TABLE 159 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 US to dominate North American market
                                      FIGURE 34 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
                                      TABLE 160 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 161 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 162 US: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 163 US: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 164 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 165 US: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Growing preference to conduct clinical trials in Canada to support market growth
                                      TABLE 166 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 167 CANADA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 168 CANADA: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 169 CANADA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 170 CANADA: DRUG DISCOVERY SERVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 171 CANADA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.2.3 NORTH AMERICA: RECESSION IMPACT
     11.3 EUROPE 
             TABLE 172 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 173 EUROPE: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 174 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 175 EUROPE: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
             TABLE 176 EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
             TABLE 177 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             TABLE 178 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Germany to hold largest share of European market
                                      TABLE 179 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 180 GERMANY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 181 GERMANY: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 182 GERMANY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 183 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 184 GERMANY: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Government-private sector collaborations to boost market
                                      TABLE 185 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 186 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 187 UK: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 188 UK: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 189 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 190 UK: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Growing number of oncology research projects to propel market
                                      TABLE 191 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 192 FRANCE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 193 FRANCE: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 194 FRANCE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 195 FRANCE: DRUG DISCOVERY SERVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 196 FRANCE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 High number of clinical trials and low drug approval time to augment market
                                      TABLE 197 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022)
                                      TABLE 198 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 199 ITALY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 200 ITALY: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 201 ITALY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 202 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 203 ITALY: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Short study start-up times and rising R&D expenditure to augment market
                                      TABLE 204 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 205 SPAIN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 206 SPAIN: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 207 SPAIN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 208 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 209 SPAIN: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 210 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 211 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 212 REST OF EUROPE: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                        TABLE 213 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 214 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 215 REST OF EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.3.7 EUROPE: RECESSION IMPACT
     11.4 ASIA PACIFIC 
             FIGURE 35 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022)
             TABLE 216 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 217 ASIA PACIFIC: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 218 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 219 ASIA PACIFIC: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
             TABLE 220 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
             TABLE 221 ASIA PACIFIC: DRUG DISCOVERY SERVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             TABLE 222 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Robust pharma industry and presence of key CROs to account for China’s large market share
                                      TABLE 223 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 224 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 225 CHINA: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 226 CHINA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 227 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 228 CHINA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Government initiatives for drug innovation to support market growth
                                      TABLE 229 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020 VS. 2022
                                      TABLE 230 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 231 JAPAN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 232 JAPAN: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 233 JAPAN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 234 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 235 JAPAN: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Low-cost services, availability of skilled workforce, and strong government support to propel market
                                      TABLE 236 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 237 INDIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 238 INDIA: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 239 INDIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 240 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 241 INDIA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.4.4 AUSTRALIA
                        11.4.4.1 Large number of clinical trials to make Australia a favorable location for drug discovery
                                      TABLE 242 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 243 AUSTRALIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 244 AUSTRALIA: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 245 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 246 AUSTRALIA: DRUG DISCOVERY SERVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 247 AUSTRALIA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Government initiatives and growing R&D activities for drug development to drive growth
                                      TABLE 248 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 249 SOUTH KOREA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 250 SOUTH KOREA: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 251 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 252 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 253 SOUTH KOREA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 254 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 255 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 256 REST OF ASIA PACIFIC: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                        TABLE 257 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 258 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 259 REST OF ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.4.7 ASIA PACIFIC: RECESSION IMPACT
     11.5 LATIN AMERICA 
             TABLE 260 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 261 LATIN AMERICA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 262 LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 263 LATIN AMERICA: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
             TABLE 264 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
             TABLE 265 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             TABLE 266 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Brazil to dominate Latin American market
                                      TABLE 267 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 268 BRAZIL: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 269 BRAZIL: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                                      TABLE 270 BRAZIL: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                      TABLE 271 BRAZIL: DRUG DISCOVERY SERVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 272 BRAZIL: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.5.2 REST OF LATIN AMERICA
                        TABLE 273 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 274 REST OF LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 275 REST OF LATIN AMERICA: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                        TABLE 276 REST OF LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 277 REST OF LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 278 REST OF LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.5.3 LATIN AMERICA: RECESSION IMPACT
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO BOOST MARKET
                        TABLE 279 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 280 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 281 MIDDLE EAST & AFRICA: MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION)
                        TABLE 282 MIDDLE EAST & AFRICA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                        TABLE 283 MIDDLE EAST & AFRICA: DRUG DISCOVERY SERVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 284 MIDDLE EAST & AFRICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION)
             11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 246)
     12.1 OVERVIEW 
     12.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 
             FIGURE 36 KEY STRATEGIES ADOPTED BY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020–2023
     12.3 MARKET SHARE ANALYSIS 
             FIGURE 37 DRUG DISCOVERY SERVICES INDUSTRY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
             TABLE 285 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
     12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 
             FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS, 2020–2022
     12.5 COMPANY EVALUATION QUADRANT 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                       FIGURE 39 DRUG DISCOVERY SERVICES INDUSTRY: COMPANY EVALUATION QUADRANT, 2022
     12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 40 DRUG DISCOVERY SERVICES INDUSTRY: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
     12.7 COMPANY FOOTPRINT ANALYSIS 
             12.7.1 COMPANY SERVICE FOOTPRINT
             TABLE 286 SERVICE PORTFOLIO ANALYSIS: DRUG DISCOVERY SERVICES MARKET (2022)
             12.7.2 COMPANY GEOGRAPHIC FOOTPRINT
                        TABLE 287 GEOGRAPHIC REVENUE MIX: DRUG DISCOVERY SERVICES MARKET (2022)
     12.8 COMPETITIVE SCENARIO 
             TABLE 288 DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020–MARCH 2023
             TABLE 289 DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2020–MARCH 2023
             TABLE 290 DRUG DISCOVERY SERVICES MARKET: EXPANSION: JANUARY 2020–MARCH 2023
 
13 COMPANY PROFILES (Page No. - 259)
     13.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 291 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                        FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
             13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                        TABLE 292 CHARLES RIVER LABORATORIES INTERNATIONAL: BUSINESS OVERVIEW
                        FIGURE 42 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2022)
             13.1.3 WUXI APPTEC
                        TABLE 293 WUXI APPTEC: BUSINESS OVERVIEW
                        FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2021)
             13.1.4 THERMO FISHER SCIENTIFIC
                        TABLE 294 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2022)
             13.1.5 PHARMARON BEIJING CO., LTD.
                        TABLE 295 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 45 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2021)
             13.1.6 EVOTEC SE
                        TABLE 296 EVOTEC SE: BUSINESS OVERVIEW
                        FIGURE 46 EVOTEC SE: COMPANY SNAPSHOT (2021)
             13.1.7 EUROFINS SCIENTIFIC SE
                        TABLE 297 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW
                        FIGURE 47 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2022)
             13.1.8 PIRAMAL ENTERPRISES LIMITED
                        TABLE 298 PIRAMAL ENTERPRISES LIMITED: BUSINESS OVERVIEW
                        FIGURE 48 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2021)
             13.1.9 SYNGENE INTERNATIONAL LIMITED
                        TABLE 299 SYNGENE INTERNATIONAL LIMITED: BUSINESS OVERVIEW
                        FIGURE 49 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2021)
             13.1.10 CURIA GLOBAL INC.
                        TABLE 300 CURIA GLOBAL INC.: BUSINESS OVERVIEW
             13.1.11 GENSCRIPT BIOTECH CORPORATION
                        TABLE 301 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
                        FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.12 JUBILANT PHARMOVA LIMITED
                        TABLE 302 JUBILANT PHARMOVA LIMITED: BUSINESS OVERVIEW
                        FIGURE 51 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2021)
             13.1.13 FRONTAGE HOLDINGS CORPORATION
                        TABLE 303 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 52 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
             13.1.14 SHANGHAI MEDICILON INC.
                        TABLE 304 SHANGHAI MEDICILON INC.: BUSINESS OVERVIEW
             13.1.15 AURIGENE DISCOVERY TECHNOLOGIES (DR. REDDY’S LABORATORIES)
                        TABLE 305 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW
                        FIGURE 53 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2021)
             13.1.16 SYGNATURE DISCOVERY LTD.
                        TABLE 306 SYGNATURE DISCOVERY LTD: BUSINESS OVERVIEW
             13.1.17 ONCODESIGN SERVICES
                        TABLE 307 ONCODESIGN SERVICES: BUSINESS OVERVIEW
                        FIGURE 54 ONCODESIGN SERVICES: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER COMPANIES 
             13.2.1 SELVITA S.A.
             13.2.2 VIVA BIOTECH HOLDINGS
             13.2.3 TCG LIFESCIENCES PVT LTD.
             13.2.4 SHANGHAI CHEMPARTNER CO., LTD.
             13.2.5 DOMAINEX LTD.
             13.2.6 NUVISAN PHARMA HOLDING GMBH
             13.2.7 DALTON PHARMA SERVICES
             13.2.8 ARAGEN LIFE SCIENCES PVT. LTD.
             13.2.9 PROMEGA CORPORATION
 
14 APPENDIX (Page No. - 340)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Pharmaceutical Research and Manufacturers of America (PhRMA), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as personnel from pharmaceutical and biopharmaceutical industries, CDMOs and CROs, academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions, including North America, Europe, the Asia Pacific, Latin America, and Middle East and Africa. Approximately 70% and 30% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Drug Discovery Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the drug discovery services market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the drug discovery services business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.   

Bottom-up approach: Company Revenue Analysis

Drug Discovery Services Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Approach 2: Secondary Research

  • The size of the drug discovery services market was obtained from secondary sources.
  • The shares of various drug discovery services in the overall market were obtained from secondary data and validated through primary participants to arrive at the total market. 
  • Primary participants validated the numbers.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition:

Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit to lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery services are provided by contract research organizations (CROs) to pharmaceutical companies.

Key Stakeholders

  • Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Drug Discovery Service Providers
  • Venture Capitalists and Investors
  • Contract Research Organizations
  • Government Associations
  • Healthcare Associations/Institutes
  • Business Research & Consulting Service Providers

Report Objectives

  • To define, describe, and forecast the drug discovery services market by type, drug type, process, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to the individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their market shares and core competencies in the global market
  • To track and analyze competitive developments such as product & service launches, partnerships, collaborations, agreements, expansions, and acquisitions in the global market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the RoE market, by country
  • Further breakdown of the RoAPAC market, by country
  • Further breakdown of the RoLA and MEA market, by country

Company Information

  • Detailed analysis and profiling of additional market players (Up to five)

Segment Analysis

  • Further breakdown of the therapeutic area segment as per the service portfolio of prominent players operating in the market.  
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 5682
Published ON
Mar, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback